Company / Cash per Share
Monopar Therapeutics Cash per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$10.13
FY2025
5-year range
$0.56 / $15.37
FY2021-FY2025
Trend
-34.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash per Share has fluctuated over the past 5 years, ranging from $0.56 in FY2023 to $15.37 in FY2024.
Based on SEC 10-K filings.
10.13 in FY2025.
Improved from $0.56 to $10.13 over the past 2 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash per share decreased 34.1% year-over-year.
- Peak cash per share was recorded in FY2024.
- Lowest cash per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.13 | -34.1% |
| FY2024 | $15.37 | +2638.6% |
| FY2023 | $0.56 | -60.5% |
| FY2019 | $1.42 | +91.7% |
| FY2018 | $0.74 | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026